Rise Advisors’s Moderna MRNA Stock Holding History

Rise Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-378	Closed	-$9.76K	–	940
2025 Q3	$9.76K	Sell	378 -18	-5%	-$502	﹤0.01%	1009
2025 Q2	$10.9K	Buy	396 +18	+5%	+$474	﹤0.01%	945
2025 Q1	$10.7K	Buy	378 +73	+24%	+$2.59K	﹤0.01%	920
2024 Q4	$12.7K	Sell	305 -19	-6%	-$908	0.01%	910
2024 Q3	$21.7K	Hold	324	–	–	0.01%	638
2024 Q2	$38.5K	Buy	324 +8	+3%	+$1.01K	0.02%	291
2024 Q1	$33.7K	Buy	316 +286	+953%	+$28.8K	0.02%	332
2023 Q4	$2.98K	Hold	30	–	–	﹤0.01%	428
2023 Q3	$3.1K	Buy	30 +3	+11%	+$335	﹤0.01%	417
2023 Q2	$3.28K	Hold	27	–	–	﹤0.01%	458
2023 Q1	$4.15K	Hold	27	–	–	﹤0.01%	479
2022 Q4	$4.85K	Hold	27	–	–	﹤0.01%	447
2022 Q3	$3K	Hold	27	–	–	﹤0.01%	504
2022 Q2	$4K	Hold	27	–	–	﹤0.01%	476
2022 Q1	$5K	Hold	27	–	–	﹤0.01%	428
2021 Q4	$6.86K	Buy	+27	New	+$7.89K	0.01%	368

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Rise Advisors's MRNA Position: Q4 2025 in Review

Rise Advisors sold out of Moderna (MRNA) in Q4 2025, closing a stake of 378 shares — an estimated $9.76K sold.

Rise Advisors first reported a position in MRNA in Q4 2021 and held it in 16 quarters. The position peaked at $38.5K in Q2 2024. 675 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

Rise Advisors reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 378 Moderna shares in Q4 2025, an estimated $9.76K.
Rise Advisors first reported a position in Moderna in Q4 2021 and held it in 16 quarters.
Rise Advisors's Moderna position peaked at $38.5K in Q2 2024.
675 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.